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Abstract
Rationale: Ever-smokers without airﬂow obstruction scores greater
than or equal to 10 on the COPD Assessment Test (CAT) still have
frequent acute respiratory disease events (exacerbation-like),
impaired exercise capacity, and imaging abnormalities. Identiﬁcation
of these subjects could provide new opportunities for targeted
interventions.
Objectives: We hypothesized that the four respiratory-related
items of the CAT might be useful for identifying such individuals,
with discriminative ability similar to CAT, which is an eight-item
questionnaire used to assess chronic obstructive pulmonary disease
impact, including nonrespiratory questions, with scores ranging
from 0 to 40.
Methods: We evaluated ever-smoker participants in the
Subpopulations and Intermediate Outcomes in COPD Study without
airﬂow obstruction (FEV1/FVC >0.70; FVC above the lower limit of
normal). Using the area under the receiver operating characteristic
curve, we compared responses to both CAT and the respiratory
symptom–related CAT items (cough, phlegm, chest tightness,
and breathlessness) and their associations with longitudinal
exacerbations. We tested agreement between the two strategies
636

(k statistic), and we compared demographics, lung function, and
symptoms among subjects identiﬁed as having high symptoms by
each strategy.
Results: Among 880 ever-smokers with normal lung function
(mean age, 61 yr; 52% women) and using a CAT cutpoint greater than
or equal to 10, we classiﬁed 51.8% of individuals as having high
symptoms, 15.3% of whom experienced at least one exacerbation
during 1-year follow-up. After testing sensitivity and speciﬁcity of
different scores for the ﬁrst four questions to predict any 1-year followup exacerbation, we selected cutpoints of 0–6 as representing a low
burden of symptoms versus scores of 7 or higher as representing a high
burden of symptoms for all subsequent comparisons. The four
respiratory-related items with cutpoint greater than or equal to 7 selected
45.8% participants, 15.6% of whom experienced at least one
exacerbation during follow-up. The two strategies largely identiﬁed the
same individuals (agreement, 88.5%; k = 0.77; P , 0.001), and the
proportions of high-symptoms subjects who had severe dyspnea were
similar between CAT and the ﬁrst four CAT questions (25.9% and
26.8%, respectively), as were the proportions reporting impaired quality
of life (66.9% and 70.5%, respectively) and short walking distance
(22.4% and 23.1%, respectively). There was no difference in area under
the receiver operating characteristic curve to predict 1-year follow-up
exacerbations (CAT score >10, 0.66; vs. four respiratory items from
AnnalsATS Volume 14 Number 5 | May 2017
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CAT >7 score, 0.65; P = 0.69). Subjects identiﬁed by either method also
had more depression/anxiety symptoms, poor sleep quality, and greater
fatigue.

well as the CAT did. These data suggest that simpler strategies
can be developed to identify these high-risk individuals in primary
care.

Conclusions: Four CAT items on respiratory symptoms identiﬁed
high-risk symptomatic ever-smokers with preserved spirometry as
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The presence of airﬂow obstruction (deﬁned
by FEV1/FVC ratio .0.7) is one of the
requirements for the diagnosis of chronic
obstructive pulmonary disease (COPD) (1).
However, there is growing recognition of the
presence of chronic bronchitis symptoms (2),
physical activity limitation, and acute
respiratory events (exacerbation-like
episodes) (3, 4) among ever-smokers without
airﬂow obstruction so deﬁned (2, 3, 5).
The COPD Assessment Test (CAT) is
an eight-item questionnaire that includes
not only items focused on respiratory
symptoms (ﬁrst four questions) but also
questions regarding activity limitation,
energy, and sleep (last four questions) (6).
Woodruff and colleagues recently
demonstrated that the well-validated CAT,
using the cutpoint of greater than or equal
to 10 points as recommended by Global
Initiative for Chronic Obstructive Lung
Disease (GOLD) guidelines, can reasonably
discriminate those individuals at risk of
exacerbations (3). The CAT is indicated for
use in patients meeting a spirometry-based
diagnosis of COPD, however, and is not
widely used in primary care, making it
necessary to develop and test novel strategies
for identiﬁcation of these high-risk subjects.

In the present study, using data from
the same cohort, we tested if these subjects
with normal airﬂow but at high risk for
respiratory events could be more easily
identiﬁed using selected questions from
the CAT, a strategy with potential for
wider use in primary care. Speciﬁcally,
we hypothesized that among ever-smokers
without spirometrically deﬁned airﬂow
obstruction, rating of respiratory symptoms
using the ﬁrst four items (respiratory
symptom–related questions) from the CAT
would identify similar individuals and
would perform similarly to the CAT in the
ability to identify subjects with increased
risk for acute respiratory events.

disease progression. SPIROMICS included
subjects aged 40–80 years in different strata,
including healthy never-smokers (<1
pack-year of tobacco smoking history) and
current or former smokers with a smoking
history of greater than 20 pack-years,
with or without obstructive lung disease.
For the present analyses, we included
ever-smoker (current or former)
SPIROMICS participants without airﬂow
obstruction (deﬁned as post-bronchodilator
FEV1/FVC >0.70 and FVC greater than the
lower limit of normal). SPIROMICS was
approved by the institutional review boards
at all participating centers, including the
University of Michigan, where the present
analyses were performed. All participants
provided written informed consent.

Methods
Measurements
Study Design and Participants

This is a cross-sectional and longitudinal
analysis of data from selected participants in
the National Institutes of Health–sponsored
Subpopulations and Intermediate Outcome
Measures in COPD Study (SPIROMICS)
(7), a prospective cohort study in which
researchers enrolled 2,981 participants with
the goals of identifying new COPD
subgroups and intermediate markers of
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Participants provided information on
demographics, smoking status (former
or current) and history, and physiciandiagnosed diseases via standardized
questionnaires. All participants had baseline
spirometry measures, for which
SPIROMICS uses post-bronchodilator
spirometry values, with spirometry
performed following American Thoracic
Society recommendations on a
637
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pneumotachograph spirometer, with
predicted values based on Hankinson
reference equations (8).
At enrollment, we obtained
information on the following markers of
respiratory impairment: presence of chronic
bronchitis symptoms (deﬁned as cough
and phlegm production for >3 consecutive
mo per yr for 2 or more yr, based on the
response to the questions on cough and
phlegm production from the American
Thoracic Society Respiratory Epidemiology
Questionnaire) (9), dyspnea severity using
the modiﬁed Medical Research Council
dyspnea scale (mMRC) score (10) (further
categorized as 0–1 and 2–4 as per GOLD
recommendations [1]), distance walked in a
6-minute walk test (used in analyses as a
continuous variable or further categorized
as ,250 m and >250 m) (5), respiratory
events or exacerbations in the 1 year prior
to enrollment, and health-related qualityof-life metrics using the St. George’s
Respiratory Questionnaire (continuous
variable and with scores categorized as <25
and .25) (11).
We also collected information on
the presence of anxiety and depression
symptoms using the Hospital Anxiety and
Depression Scale (further categorized as
score >8 representing high symptoms) (12),
sleep quality measured by the Pittsburgh
Sleep Quality Index (with score .5
indicating poor sleep quality) (13),
fatigue using the Functional Assessment
of Chronic Illness Therapy–Fatigue scale
(with values <33 considered as signiﬁcant
fatigue) (14), and exercise tolerance
using the Veterans Speciﬁc Activity
Questionnaire (with predicted ability
less than 5 metabolic equivalents being
considered as low exercise tolerance) (15).
Participants in the present analysis were
followed every 3 months for 1 year
to identify acute respiratory disease events
(hereafter described as exacerbations),
deﬁned as use of antibiotic agents, systemic
glucocorticoids, or both or as need for
unplanned ofﬁce, emergency department,
or admissions because of respiratory
symptoms (exacerbations requiring health
care use) (7).
To identify subjects with a high burden
of symptoms, we used the CAT, a validated
health status questionnaire with recall
time of 6 weeks, which includes eight
questions, each rated on a 5-point scale (6).
CAT is a copyrighted instrument used in
SPIROMICS under license agreement with
638

its proprietor. We selected CAT as the
deﬁnition of symptom burden because it is
part of the GOLD recommendations (1).
For the present analyses, we compared
two different strategies to identify highsymptoms subjects. In the ﬁrst, we used the
CAT (scale 0–40, with 0–9 classiﬁed as low
symptom burden and >10 as high
symptom burden, as recommended by
GOLD strategy document) (1). In the
alternate method, we used only the ﬁrst
four items (respiratory symptom–related
questions) of the CAT, which resulted in
a score of 0–20. We identiﬁed a cutpoint
for the four questions testing associations
between all possible scores and based on
its associations with any 1-year follow-up
exacerbation. We took this approach
because there are no normative values
derived from four items, but for the
complete instrument (16), CAT
questionnaires were applied at enrollment
by trained research coordinators who were
unware of the planned analyses.
Statistical Analysis

Descriptive statistics were based on
proportions and means (with SD),
according to the variable of interest. The
agreement between CAT and the respiratory
question subset of CAT to identify similar
groups of participants as having a high
burden of symptoms was calculated using
the k statistic. To compare both CAT and
the ﬁrst four questions with the predeﬁned
cutpoints, we tested their association with
other measures of health impact and
impairment, which were selected as the
reference standard.
For a cross-sectional comparison,
we tested associations with health-related
quality of life, which we measured by
St. George’s Respiratory Questionnaire
total score, walking distance, and baseline
exacerbations. During longitudinal followup, we used as a reference the associations
with exacerbations/acute respiratory events
during 1-year follow-up. The association was
measured by the area under the receiver
operating characteristic curve (AUC), and
the AUCs were compared. The analysis
assumed an AUC of 0.68 for the association
between CAT and any exacerbation during
the 1-year follow-up, and, using a probability
of type I error of 5% and a power of 80%
to detect a 5% difference between CAT and
the respiratory item subset, inclusion of at
least 707 participants would allow detection
of a difference of 0.05 between AUCs.

We also calculated the sensitivity and
speciﬁcity of CAT and the ﬁrst four items
to predict any exacerbation during followup. Finally, in prespeciﬁed analyses, we
tested if the strategies had similar
performance across different demographic
groups deﬁned by age, sex, and race. All
analyses were conducted using STATA
version 12 software (StataCorp, College
Station, TX), and a P value less than 0.05
was considered signiﬁcant.

Results
We included 880 ever-smokers with preserved
lung function among the 2002 SPIROMICS
participants. Figure E1 in the online
supplement shows the ﬂow of participants
through the present study. Overall, half of the
ever-smokers with preserved lung function
were women, one-fourth were of African
American race, and half were current
smokers. Participants described the presence
of chronic bronchitis symptoms (18.6%),
dyspnea with mMRC score greater than
or equal to 2 (15.5%), and short walking
distance (15.9%). Among different comorbid
conditions reported were obesity (deﬁned
as body mass index [BMI] >30 kg/m2) in
40% and asthma in 18% (Table E1).
After testing sensitivity and
speciﬁcity of different scores of the ﬁrst four
questions to predict any 1-year follow-up
exacerbation, we selected scores of 0–6 as
a low burden of symptoms and 7 or higher
as a high burden of symptoms, and these
were used as cutpoints for all subsequent
comparisons. The sensitivity and speciﬁcity
for all possible cutpoints are presented
in Table E2. Using the CAT with a cutpoint
of greater than or equal to 10 points,
we identiﬁed 456 participants with
high symptom burden. Using the four
respiratory items of CAT only, score greater
than or equal to 7 points identiﬁed 403
subjects with high symptom burden. The
agreement was 88.5% (k = 0.77; P , 0.001).
Both groups had similar demographic
and clinical characteristics (Table 1).
At enrollment, the proportion of highsymptoms subjects who had severe dyspnea
was similar between the CAT and the ﬁrst
four CAT questions (25.9% and 26.8%,
respectively), as were the frequencies with
which subjects reported impaired quality of
life (66.9% and 70.5%, respectively) and had
short walking distance (22.4% and 23.1%,
respectively) (Table 2).
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Table 1. Description of participants with preserved spirometry identiﬁed as high symptom burden by two different methods (n = 880)

Demographics
Age, yr, mean (SD)
Female sex, %
African American race, %
BMI, kg/m2, mean (SD)
Smoking history
Pack-years, mean (SD)
Currently smoking, %
Lung function
FEV1, L, mean (SD)
FEV1, % predicted, mean (SD)
Comorbid conditions, %
Obesity (BMI >30 kg/m2)
Asthma
Diabetes
Coronary artery disease
Markers of respiratory impact, %
Any respiratory event prior to enrollment
Chronic bronchitis symptoms*
mMRC dyspnea score >2†
Short distance during 6-min walk test‡
Impaired quality of life measured by SGRQ total scorex
Any of the above
CAT score, mean (SD)

P Value

Identiﬁed by CAT >10
points (n = 456)

Identiﬁed by Respiratory
Questions of CAT >7
points (n = 403)

59.4 (9.9)
55.7
33.8
29.8 (5.4)

59.1 (9.7)
56.6
33.5
29.8 (5.4)

0.74
0.78
0.92
1

46.1 (26.4)
57.2

45.8 (26.6)
58.3

0.59
0.74

2.61 (0.70)
92.0 (14.7)

2.61 (0.70)
92.2 (14.0)

1
0.38

48.7
27.6
19.3
5.9

48.1
29.3
19.1
5.7

0.85
0.58
0.94
0.99

22.8
30.9
25.9
22.4
66.9
80.7
17.9 (6.4)

24.6
35.0
26.8
23.1
70.5
83.6
18.3 (6.7)

0.53
0.20
0.76
0.81
0.25
0.26
0.20

Definition of abbreviations: BMI = body mass index; CAT = COPD Assessment Test; mMRC = modified Medical Research Council dyspnea scale;
SGRQ = St. George’s Respiratory Questionnaire.
P value represents comparison of means or proportions among those identified by each strategy.
*Chronic bronchitis was defined as cough and phlegm production for at least 3 consecutive months per year for at least 2 years.
†
Dyspnea was defined as mMRC score greater than or equal to 2.
‡
Short walking distance was defined as distance walked in 6 minutes less than 250 m.
x
Impaired quality of life was defined as an SGRQ total score greater than 25.

Among participants identiﬁed with
high symptom burden by CAT, 15.1% had
at least one exacerbation during the ﬁrst
year of follow-up. For those identiﬁed by
the respiratory symptoms questions of
CAT, the frequency was 14.1%. The
association between high symptom
burden by CAT (score >10 points) and
any exacerbation during follow-up had an
AUC of 0.66, whereas for the ﬁrst four
CAT questions (score >7 points), the
AUC was 0.65 (P = 0.69 for comparison of
the two curves).
When exacerbations were classiﬁed by
use of antibiotics/steroids, the AUCs were
0.65 and 0.65, respectively (P = 0.76 for
comparison of both curves). For
exacerbations requiring health care use,
the AUCs were 0.65 and 0.64, respectively
(P = 0.58 for comparison of the two curves)
(Table 2). A cutpoint of 10 using CAT was
associated with a sensitivity of 0.80 and
a speciﬁcity of 0.52 for any exacerbation,
whereas the cutpoint of 7 for the selected

respiratory items of CAT resulted in a
sensitivity of 0.73 and a speciﬁcity of 0.58.
Similar associations were found for the
presence of different markers of respiratoryrelated impairment at enrollment. The
association between high symptom burden
by CAT (score >10 points) and impaired
quality of life at enrollment showed an
AUC of 0.81, whereas for the ﬁrst four CAT
questions (score >7 points), the AUC was
0.81 (P = 0.87 for comparison of both
curves). The association of CAT score
greater than or equal to 10 points and short
walking distance showed an AUC of 0.62,
whereas for the selected CAT items
(score >7 points), the AUC was 0.62
(P = 0.86 for comparison of both curves)
(Table 2).
Because CAT includes questions on
health status that are not necessarily
respiratory related, we also tested whether
subjects identiﬁed with high symptoms
(using any strategy) could also have other
markers of health impairment not related

Martinez, Murray, Barr, et al.: Four Respiratory Questions of COPD Assessment Test

exclusively to respiratory function. We
found that, compared with those in the lowsymptom category, subjects reported with
higher frequency a high burden of anxiety
and depression symptoms, more frequently
had low ability to exercise, and reported fatigue
and had poor-quality sleep with higher
frequency. These additional health concerns
had a similar frequency in the high-symptom
group, regardless of the strategy used to
identify them (CAT or respiratory questions of
CAT) (Table 3).
The two scoring strategies had an
agreement of 88.5% in subject classiﬁcation
(400 subjects classiﬁed as low risk and 379 as
high risk by both strategies), leaving 101
discordant subjects. The majority of
discordant cases (n = 77) were subjects
classiﬁed as having low symptoms on the
basis of the ﬁrst four questions of CAT but
as having high symptoms using the CAT
questionnaire. When we compared these 77
discordant subjects with the 400 judged as
having low symptoms on the basis of both
639
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Table 2. Use of two strategies used to identify subjects with high symptom burden to predict quality of life, physical activity, and
exacerbations (n = 880)
CAT >10 points
AUC (95% CI)
Cross-sectional associations
Any respiratory event prior to enrollment
Dyspnea*
Short distance in 6-min walk test†
Impaired quality of life measured by SGRQ total
score‡
Longitudinal exacerbations (during 1-yr follow-up)
Any
Any requiring steroids or antibiotics
Any requiring health-care use

0.66
0.70
0.62
0.81

Respiratory Questions of CAT >7
points AUC (95% CI)

(0.62–0.70)
(0.67–0.74)
(0.58–0.66)
(0.79–0.83)

0.67
0.69
0.62
0.81

0.66 (0.61–0.70)
0.65 (0.60–0.70)
0.65 (0.60–0.69)

P Value

(0.63–0.71)
(0.66–0.73)
(0.57–0.66)
(0.78–0.83)

0.77
0.59
0.86
0.87

0.65 (0.60–0.70)
0.65 (0.60–0.71)
0.64 (0.58–0.69)

0.69
0.76
0.58

Definition of abbreviations: AUC = area under the receiver operating characteristic curve; CAT = COPD Assessment Test; CI = confidence interval;
SGRQ = St. George’s Respiratory Questionnaire.
P value is for the comparison of AUCs.
*Dyspnea was defined as modified Medical Research Council dyspnea scale score greater than or equal to 2.
†
Short walking distance was defined as distance walked in 6 minutes less than 250 m.
‡
Impaired quality of life was defined as SGRQ total score higher than 25.

strategies, they were more frequently
current smokers, had higher BMI, and
more frequently were of African American
race (Table E3). We found that compared
with results for male participants, when
applied to females, both strategies had
higher sensitivity but lower speciﬁcity.
Similarly, higher sensitivity and lower
speciﬁcity were found for both strategies in
African American participants (compared
with whites) and current smokers (versus
former smokers). CAT also had slightly
higher sensitivity than CAT respiratory

questions when applied to women and
African Americans (Table E4).
Finally, we tested if just asking
participants about the presence of dyspnea
(mMRC greater than or equal to 2), the
alternate way to identify subjects with highsymptoms COPD according to the GOLD
recommendations (1), could identify
subjects similarly to the four respiratoryrelated items of CAT. We found that the
AUC of 0.59 (95% conﬁdence interval,
0.60–0.70) to predict 1-year exacerbations
was signiﬁcantly lower when using mMRC

Table 3. Additional markers of health impairment among participants with preserved
lung function identiﬁed as high symptom burden by two different methods (n = 880)

High burden of anxiety
symptoms*
High burden of depression
symptoms†
Poor sleep quality‡
Fatiguex
Low exercise tolerancek

P Value

Identiﬁed by
CAT >10
points (n = 456)

Identiﬁed by Respiratory
Questions of
CAT >7 points (n = 403)

42.8

44.9

0.53

24.3

25.8

0.61

63.2
41.9
59.9

67.5
41.9
60.8

0.18
1.0
0.78

Definition of abbreviation: CAT = COPD Assessment Test.
Data shown as percentage. P value represents comparison of means or proportions among those
identified by each strategy.
*High burden of anxiety symptoms was defined as Hospital Anxiety and Depression Scale anxiety
score greater than or equal to 8.
†
High burden of depression symptoms was defined as Hospital Anxiety and Depression Scale
depression score greater than or equal to 8.
‡
Poor sleep quality was defined as Pittsburgh Sleep Quality Inventory score greater than 5.
x
Fatigue defined was defined as Functional Assessment of Chronic Illness Therapy–Fatigue scale
score greater than or equal to 33.
k
Low exercise was defined as Veterans Specific Activity Questionnaire score less than 5 metabolic units.
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greater than or equal to 2 (P = 0.04 for
comparison of the two curves).

Discussion
We found that the four respiratory
symptom items of the CAT, using a
threshold of 7 points or higher, identiﬁed a
group of former or current smokers with
preserved spirometry similar to those
selected using the CAT with a threshold
10 points or higher. Both groups had similar
symptom burden, and both strategies
were comparable in their prediction of
respiratory events (exacerbations) during
longitudinal follow-up. These ﬁndings
conﬁrm previous reports about the high
frequency of symptoms of respiratory
impairment among ever-smokers who do
not satisfy the current spirometric deﬁnition
of COPD (2, 3, 5), and they also provide a
proof of the concept that simpler strategies
can be developed and tested to identify
these subjects in primary care. For example,
in the present study, the decision about the
cutpoint selection when using the selected
items of CAT was based on a trade-off
between sensitivity and speciﬁcity of
all possible scores in the participant
population, but it is unclear if this can
be extrapolated to other studies without
further validation.
The current deﬁnition of COPD relies
on the presence of spirometric measures of
airﬂow obstruction (1). However, it is clear
that not all current and former smokers
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without airﬂow obstruction are free of a
disease. Growing evidence from several
cohorts suggests that individuals with
smoking history without airﬂow
obstruction may still have signiﬁcant
respiratory symptoms and are at risk for
poor outcomes, in some cases similar to
those of individuals with established airﬂow
obstruction. Efforts to prevent further
clinical deterioration and poor outcomes
among smokers with preserved spirometry
should start by testing different tools
to identify this at-risk population.
SPIROMICS investigators have
previously demonstrated that the wellvalidated CAT, using the cutpoint of
10 points or o higher as recommended
by GOLD guidelines, can reasonably
discriminate those individuals at risk of
exacerbations (3), ﬁndings that are aligned
with what is known about subjects with
established COPD. We extend these
ﬁndings by showing that using the
respiratory questions of CAT with a
cutpoint score of 7 points or higher has
similar associations with clinical descriptors
of respiratory impairment (short walking
distance, more severe dyspnea, impaired
quality of life) and longitudinal
exacerbations, as shown by similar
AUCs using any of those strategies.
The differences between subjects
scoring less than 7 points versus those
scoring 7 points or higher on the four
respiratory questions of CAT are similar in
magnitude and direction to those previously
reported by Woodruff and coworkers (3), as
shown in Table E5. Our ﬁndings provide
evidence that using only respiratory
symptom–related questions could facilitate
identiﬁcation of these subjects by busy
primary care providers, expanding the
available tools for identiﬁcation of eversmokers without airﬂow obstruction but
at risk of poor outcomes. In the present
study, CAT and selected CAT respiratory
questions not only had a similar overall
classiﬁcation of high-symptoms subjects, as
measured by the AUC, but also had very
similar sensitivity and speciﬁcity. CAT was
associated with a sensitivity of 0.80 and a
speciﬁcity of 0.52 for any 1-year follow-up
exacerbation, whereas the respiratory
questions of the CAT had a sensitivity
of 0.73 and a speciﬁcity of 0.58.
CAT and the selected CAT respiratory
questions exhibited signiﬁcant agreement in
determining subjects with high burden of
symptoms, but they also were discordant

in some subjects. Some of the discordant
individuals belong to groups for whom there
is previous evidence of disparities in
respiratory care; hence, we examined
them in more detail. Women have been
recognized as being diagnosed with
obstructive lung disease with lower
frequency than men (17), even in the
presence of similar symptoms. We found
that both strategies to identify high
symptoms in smokers with normal lung
function have similar AUC, whereas the
speciﬁcity of the respiratory items of CAT
is slightly better than that of CAT. The
strategies to identify subjects with high
symptom burden also perform well among
former smokers, and actually using the ﬁrst
four questions of CAT had high sensitivity
and speciﬁcity in this group.
An interesting ﬁnding which deserves
further exploration is that both CAT and the
respiratory questions of CAT were
associated with a low speciﬁcity among
participants of African American race,
although the speciﬁcity was slightly higher
with the respiratory questions. This ﬁnding
is relevant because African Americans are a
population group for whom there is a need
to develop better models to understand the
impact of tobacco-related lung disease
(18, 19). Still, among African Americans,
the sensitivity of both strategies was as high
as or higher than in other groups. Overall, it
is worth recognizing that the classiﬁcation
statistics (sensitivity and speciﬁcity) and
discriminative ability (AUCs around 0.65)
of both strategies need to be improved in
the future. Still, they represent an advance
because they are calling attention to a
group of subjects previously considered
“healthy smokers” owing to the absence of
airﬂow obstruction, at least as deﬁned by
FEV1/FVC less than 70%. The values
are also similar to what was previously
reported using the CAT with similar
subjects (3).
Limitations

Our study is subject to several limitations.
The most important is that it is not
based on a representative sample of the
population; it is based on research
volunteers recruited at tertiary care medical
centers. However, the sample was inclusive
and had a large proportion of women
and minority participants, which makes
the results easier to translate into clinical
practice. Our analyses could be interpreted
as a comparison of diagnostic and prognostic
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tools, and we agree with that idea and present
a complete description using the Standards
for Reporting Diagnostic Accuracy Studies
recommendations in Table E6 (20).
Unfortunately, the two diagnostic
strategies lack a clearly deﬁned gold
standard with which to be compared. To
minimize this potential limitation, we
used for comparison an outcome standard
(exacerbation during follow-up) and
additional cross-sectional reference
standards using patient characteristics not
included in the CAT (walking distance,
quality-of-life metrics).
In the present study, we used the
responses to selected CAT items to
understand which areas of the participants’
health were more affected and if they were
strongly associated with exacerbations.
Nonetheless, we should note that the
CAT was validated as an eight-item
questionnaire and that using questions
independently of each other could change
the integrity and measurement properties of
the questionnaire; an assessment of the
measurement properties that result from
reducing the number of items in this
questionnaire is beyond the scope of this
paper. Equally important, CAT was designed
to be applied to subjects with a diagnosis of
COPD, whereas our study population
consisted of participants without airﬂow
obstruction. Strengths of the study
include the detailed characterization of
participants, careful follow-up to identify
the outcome standard selected to
compare the two strategies of using the
CAT, and the robustness of results in
different disease spectra and subgroups
of subjects.
Conclusions

Using the four respiratory questions of the
CAT with a cutpoint score of 7 or higher
identiﬁes a group of smokers with preserved
spirometry similar to that identiﬁed with the
CAT cutpoint score of 10 or higher, who
have a greater burden of dyspnea, chronic
bronchitis, activity limitation, and impaired
quality of life, as well as increased risk for future
exacerbations. These ﬁndings provide further
evidence of a relationship between respiratory
symptoms and risk for respiratory events, and
they provide support for future development of
simpler strategies to identify these high-risk
subjects in primary care. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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Respiratory Symptoms Items from the CAT™ Questionnaire Identify Ever-Smokers with
Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes: An Analysis of the
SPIROMICS Cohort
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Supplementary Table 1. Description of SPIROMICS participants with preserved lung function
included in the analysis (n=880)
Demographics
Age (mean, s.d.)
Female gender (%)
African American (%)
BMI (mean, s.d.)
Smoking history
Pack-years smoked (mean, s.d.)
Currently smoking (%)
Lung function
FEV1 in liters (mean, s.d.)
FEV1 % predicted (mean, s.d.)
Markers of respiratory impact
Any respiratory event prior to enrollment
Chronic bronchitis symptoms
Dyspnea
Low walking distance
High SGRQ
Comorbid Conditions (%)
Obesity (BMI ≥30 kg/m2)
Asthma
Diabetes
Coronary artery disease

60.7 (9.8)
51.6
25.6
28.8 (5.2)
44.0 (24.1)
49.7
2.73 (0.72)
95.0 (14.2)
14.9
18.6
15.5
15.9
38.2
40.0
18.3
14.1
5.1
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Supplementary Table 2. Sensitivity and specificity for any one-year follow-up exacerbation for
each possible score using only the first four items of CAT
Score

Area under the curve ROC

Sensitivity

Specificity

1

0.503

0.95

0.05

2

0.537

0.95

0.12

3

0.563

0.85

0.22

4

0.602

0.88

0.32

5

0.612

0.81

0.41

6

0.623

0.74

0.50

7

0.654

0.73

0.57

8

0.674

0.69

0.65

9

0.642

0.55

0.72

10

0.632

0.48

0.77

11

0.611

0.39

0.82

12

0.601

0.32

0.87

13

0.599

0.29

0.90

14

0.577

0.22

0.93

15

0.545

0.14

0.95

16

0.527

0.08

0.97

17

0.513

0.04

0.98

18

0.500

0.01

0.98
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Supplementary Table 3. Description of participants classified as discordant by two methods
used to identify subjects with high symptom burden preserved lung function (n=880)
Low symptoms
Low symptoms
P=value
by both methods
by respiratory
(n=400)
questions of
CAT only
(n=77)
Demographics
Age (mean, s.d.)
62.3 (9.5)
60.6 (10.6)
0.17
Female gender (%)
47.0
49.3
0.70
African American (%)
16.2
32.5
0.005
BMI (mean, s.d.)
27.8 (4.8)
29.1 (5.2)
0.02
Smoking history
Pack-years smoked (mean, s.d.)
42.0 (21.5)
45.0 (22.5)
0.25
Currently smoking (%)
40.0
54.6
0.02
Lung function
FEV1 in liters (mean, s.d.)
2.87 (0.72)
2.64 (0.66)
0.01
FEV1 % predicted (mean, s.d.)
98.2 (13.0)
92.9 (17.1)
0.002
Markers of respiratory impact
Any respiratory event prior to
6.5
7.8
0.67
enrollment (%)
Chronic bronchitis symptoms
4.0
9.1
0.06
(%)
mMRC score ≥2
4.0
15.6
<0.001
Six minute walking distance
9.0
14.3
0.15
<250 m
Comorbid Conditions (%)
Obesity (BMI ≥30 kg/m2)
30.8
45.5
0.01
Asthma
8.0
14.3
0.07
Diabetes
8.3
16.9
0.04
Coronary artery disease
4.5
5.2
0.72

E4

Supplementary Table 4. Association of CAT and first four CAT questions with any
exacerbation during longitudinal follow-up in selected groups of participants
CAT

Respiratory questions of

≥10 points

CAT
≥7 points

Subgroup (n)

By gender
Women (n=437)
Men (n=394)
By race
African Americans
(n=203)
Non-Hispanic Whites
(n=581)
By chronic bronchitis
No chronic bronchitis
(n=678)
Chronic bronchitis
(n=153)
By smoking status
Former smokers (n=422)
Current smokers (n=400)
By Body mass
Obese [BMI ≥30] (n=337)
Normal or overweight
(n=494)
By Asthma status
Participants with asthma
(n=161)
Participants without
asthma (n=719)

AUC
(95% CI)

Sensitivity
/
Specificity

AUC
(95% CI)

Sensitivity
/
Specificity

0.66
(0.60, 0.71)
0.64
(0.56, 0.72)

0.83 / 0.49

0.65
(0.59, 0.71)
0.63
(0.54, 0.72)

0.78 / 0.53

0.65
(0.60, 0.71)
0.65
(0.60, 0.71)

0.95 / 0.36

0.62
(0.53, 0.71)
0.65
(0.59, 0.72)

0.82 / 0.43

0.65
(0.59, 0.71)
0.56
(0.52, 0.61)

0.72 / 0.59

0.63
(0.56, 0.70)
0.56
(0.52, 0.61)

0.61 / 0.66

0.67
(0.61, 0.74)
0.64
(0.57, 0.70)

0.75 / 0.60

0.68
(0.61, 0.75)
0.61
(0.54, 0.68)

0.71 / 0.66

0.60
(0.54, 0.67)
0.68
(0.62, 0.75)

0.81 / 0.40

0.60
(0.53, 0.67)
0.68
(0.61, 0.76)

0.73 / 0.48

0.59
(0.53, 0.65)
0.64
(0.58, 0.71)

0.91 / 0.27

0.60
(0.53, 0.67)
0.63
(0.56, 0.70)

0.89 / 0.31

0.74 / 0.55

0.73 / 0.57

0.96 / 0.17

0.84 / 0.43

0.79 / 0.59

0.73 / 0.56
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0.64 / 0.61

0.69 / 0.62

0.96 / 0.17

0.74 / 0.48

0.73 / 0.63

0.63 / 0.62

Supplementary Table 5. Comparison of participants with preserved lung function scoring <7
versus those scoring ≥7 points on the four respiratory questions of CAT (n=880)
CAT score

CAT score

p-value

<7 points

≥7 points

(n=477)

(n=403)

62.0 (9.7)

59.1 (9.7)

<0.001

Female gender (%)

47.4

56.6

0.007

African American (%)

18.9

33.5

<0.001

28.0 (4.8)

29.8 (5.4)

<0.001

42.5 (21.7)

45.8 (26.6)

0.04

42.4

58.3

<0.001

FEV1 in liters (mean, s.d.)

2.83 (0.71)

2.61 (0.71)

<0.001

FEV1 % predicted (mean,
s.d.)

97.3 (13.9)

92.2 (14.0)

<0.001

Obesity (BMI ≥30 kg/m2)

33.1

48.1

<0.001

Asthma

9.0

29.3

<0.001

Diabetes

9.6

19.1

<0.001

Coronary artery disease

4.6

5.7

0.74

Demographics
Age (mean, s.d.)

BMI (mean, s.d.)
Smoking history
Pack-years smoked (mean,
s.d.)
Currently smoking (%)
Lung function

Comorbid Conditions (%)

Markers of respiratory impact (%)

E6

Any respiratory event prior
to enrollment

6.7

24.6

<0.001

Chronic bronchitis symptoms

4.8

35.0

<0.001

mMRC dyspnea score ≥2

5.9

26.8

<0.001

Low distance during 6minute walking test

9.9

23.1

<0.001

Impaired quality-of-life by
SGRQ total score

10.9

70.5

<0.001

Any of the above

27.9

83.6

<0.001

6.0 (4.0)

18.0 (7.0)

<0.001

CAT score
CAT score (mean, s.d.)

Additional markers of health impairment
High burden of anxiety
symptoms

17.8

44.9

<0.001

High burden of depression
symptoms

5.5

25.8

<0.001

Poor sleep quality

49.1

67.5

<0.001

Fatigue

9.0

41.9

<0.001

Low exercise tolerance

23.3

60.8

<0.001

Notes: p-value represents comparison of means or proportions among those identified by each
strategy.
Chronic bronchitis was defined as cough and phlegm production for ≥3 consecutive months per
years for ≥2years. Dyspnea was defined as mMRC score ≥2. Low walking distance as distance
walked in six minutes <250 m. Impaired quality-of-life as SGRQ total score >25. High burden of
anxiety symptoms was defined as Hospital Anxiety and Depression (HADS) anxiety score ≥8.
High burden of depression symptoms as HADS depression score ≥8. Poor sleep quality as
Pittsburgh Sleep Quality Inventory >5. Fatigue defined as Functional Assessment of Chronic
Illness Therapy-Fatigue scale ≤33. Low exercise was defined as Veterans Specific Activity
Questionnaire <5 metabolic units.
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Supplementary Table 6. Standards for Reporting Diagnostic Accuracy Studies (STARD)
criteria followed in the current manuscript
Section & Topic

Item

Item

Reported

No.
Tittle or Abstract

1

Identification as a study of diagnostic

Yes

accuracy using at least one measure of
accuracy
Abstract

2

Structured summary of study design,
methods, results, and conclusions

Yes

Introduction

3

Scientific and clinical background,
including the intended use and clinical
role of the index test

Yes

4

Study objectives and hypotheses

Yes

Study design

5

Whether data collection was planned
before the index test and reference
standard were performed (prospective
study) or after (retrospective study)

Yes

Participants

6

Eligibility criteria

Yes

7

On what basis potentially eligible
participants were identified (such as
symptoms, results from previous tests,
inclusion in registry)

Yes

8

Where and when potentially eligible
participants were identified (setting,
location and dates)

Yes

9

Whether participants formed a
consecutive, random or convenience
series

Yes

Methods

Test methods

10b

Reference standard, in sufficient
E8

Yes

detail to allow replication

Analysis

11

Rationale for choosing the reference
standard (if alternatives exist)

Yes

12a

Definition of and rationale for test
positivity cut-offs or result categories of
the index test, distinguishing pre-specified
from exploratory

Yes

13a

Whether clinical information and
reference standard results were available
to the performers/readers of the index test

Yes

14

Methods for estimating or comparing
measures of diagnostic accuracy

Yes

15

How indeterminate index test or reference
standard results were handled

Yes

16

How missing data on the index test and
reference standard were handled

Yes

17

Any analyses of variability in diagnostic
accuracy, distinguishing pre-specified
from exploratory

Yes

18

Intended sample size and how it was
determined

Yes

Results
Participants

Yes
19

Flow of participants, using a diagram

Yes

20

Baseline demographic and clinical
characteristics of participants

Yes

21a

Distribution of severity of disease in those
with the target condition

Yes

22

Time interval and any clinical
interventions between index test and
reference standard

Yes

E9

Test results

Discussion

Other
information

23

Cross tabulation of the index test results
(or their distribution) by the results of the
reference standard

Yes

24

Estimates of diagnostic accuracy and their
precision (such as 95% confidence
intervals)

Yes

25

Any adverse events from performing the
index test or the reference standard

No

26

Study limitations, including sources of
potential bias, statistical uncertainty, and
generalizability

Yes

27

Implications for practice, including the
intended use and clinical role of the index
test

Yes

28

Registration number and name of registry

Yes

29

Where the full study protocol can be
accessed

Yes

30

Sources of funding and other support; role
of funders

Yes

Notes: For answers with Yes, we will provide the page number after there is a pdf version
available.
Based on Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential
items for reporting diagnostic accuracy studies. BMJ 2015;351:h5527.
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SPIROMICS
Participants enrolled at time
of analysis:
2,737
Exclude participants who
are never smokers:
199

2,538

Exclude participants with
FEV1/FVC < 0.7:
1,589
949
Exclude participants with
FVC < lower limit normal:
5
944
Exclude participants
without CAT scores:
64
Included in cross-sectional
analyses:
880
Participants without 1-year
follow-up:
49
Included in longitudinal
analyses:
831
Figure 1. Flow of SPIROMICS participants included in the current analysis

